Compare GTE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTE | CRDF |
|---|---|---|
| Founded | 2003 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.3M | 130.7M |
| IPO Year | 2007 | 2012 |
| Metric | GTE | CRDF |
|---|---|---|
| Price | $8.11 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | ★ 871.2K | 663.7K |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $374,460,000.00 | $365,993.00 |
| Revenue This Year | $3.67 | N/A |
| Revenue Next Year | $0.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 41.99 | ★ 49.61 |
| 52 Week Low | $3.09 | $1.48 |
| 52 Week High | $8.84 | $4.56 |
| Indicator | GTE | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 64.45 | 44.22 |
| Support Level | $3.83 | $1.51 |
| Resistance Level | N/A | $2.05 |
| Average True Range (ATR) | 0.56 | 0.12 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 75.02 | 1.96 |
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.